Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alo
Ritlecitinib has clinically meaningful and sustained efficacy beyond 1 year with a favourable safety and tolerability profile, supporting its long-term use in patients aged ≥ 12 years with AA.
Authors
- Jerry Shapiro (ORCID: https://orcid.org/0000-0002-2971-1223)
- Jennifer Soung (ORCID: https://orcid.org/0009-0009-5586-0677)
- Bianca Maria Piraccini (ORCID: https://orcid.org/0000-0001-6537-9689)
- Melissa Piliang
- Nina Magnolo (ORCID: https://orcid.org/0000-0001-6802-0153)
- Gregor Schaefer
- Lidia Rudnicka (ORCID: https://orcid.org/0000-0002-8308-1023)
- Paul Farrant (ORCID: https://orcid.org/0000-0001-9695-0884)
- Brett King (ORCID: https://orcid.org/0000-0002-4576-4616)
- Alexandre Lejeune
- Deborah Woodworth
- Xin Luo (ORCID: https://orcid.org/0000-0002-1348-5305)
- Robert A. Wolk (ORCID: https://orcid.org/0000-0001-8581-6647)
Institutions
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- Medical University of Warsaw (PL)
- Yale University (US)
- Pfizer (Germany) (DE)
- University Hospital Münster (DE)
- Pfizer (France) (FR)
- Azienda USL di Bologna (IT)
- University Hospitals Sussex NHS Foundation Trust (GB)
- New York University (US)
- University of Bologna (IT)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1093/bjd/ljae365
- Citations
- 28
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 14.45
Funders
- Pfizer